Illicit drug use in heavy smokers with and without schizophrenia

Schizophrenia Research

Volumn 139, Issue 1-3, 2012, Pages 194-200

  Mackowick, Kristen M ^a   Heishman, Stephen J ^a   Wehring, Heidi J ^b   Liu, Fang ^b   McMahon, Robert P ^b   Kelly, Deanna L ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol; Cigarettes; Drug use; Marijuana; Schizophrenia; Smoking; Tobacco

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; CANNABIS; COCAINE; ILLICIT DRUG; PSYCHEDELIC AGENT;

ADULT; AGE; AGED; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CIGARETTE SMOKING; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG USE; DSM-IV; FEMALE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING HABIT; TOBACCO DEPENDENCE;

ADULT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MARYLAND; MIDDLE AGED; OUTPATIENTS; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84863785153     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.04.012     Document Type: Article

References (73)

1. Agrawal A., Madden P.A.F., Bucholz K.K., Heath A.C., Lynskey M.T. Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug Alcohol Depend. 2008, 95(1-2):107-114.
2. Angermeyer M.C. Schizophrenia and violence. Acta Psychiatr. Scand. Suppl. 2000, 407:63-67.
3. Bechtholt A.J., Mark G.P. Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats. Psychopharmacology 2002, 162(2):178-185.
4. Breakey W.R., Goodell H., Lorenz P.C., McHugh P.R. Hallucinogenic drugs as precipitants of schizophrenia. Psychol. Med. 1974, 4(3):255-261.
5. Breese C.R., Lee M.J., Adams C.E., et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000, 23(4):351-364.
6. Byrne A., Kirby B., Zibin T., et al. Psychiatric and neurological effects of chronic inhalant abuse. Can. J. Psychiatry 1991, 36:735-738.
7. Caspi A., Moffitt T.E., Cannon M., et al. Moderation of the effect of adolescent-onset cannabis use in adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
8. Chouljian T.L., Shumway M., Balancio E., Dwyer E.V., Surber R., Jacobs M. Substance use among schizophrenic outpatients: prevalence, course, and relation to functional status. Ann. Clin. Psychiatry 1995, 7(1):19-24.
9. Compton M.T., Kelley M.E., Ramsay C.E., et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am. J. Psychiatry 2009, 166(11):1251-1257.
10. Dalack G.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomenology and laboratory findings. Am. J. Psychiatry 1998, 155(11):1490-1501.
11. Daniels A.M., Latcham R.W. Petrol sniffing and schizophrenia in a Pacific island paradise (Letter). Lancet 1984, 1(8373):389.
12. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148(11):1474-1486.
13. Daws L.C., Callaghan P.D., Morón J.A., et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 2002, 290(5):1545-1550.
14. de Leon J. Smoking and vulnerability for schizophrenia. Schizophr. Bull. 1996, 22(3):405-409.
15. de Leon J., Becona E., Gurpegui M., Conzalea-Pinto A., Diaz F.J. The association between high nicotine dependence and severe mental illness may be consistent across countries. J. Clin. Psychiatry 2002, 63(9):812-816.
16. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 1990, 16(1):55-67.
17. el Guebaly N., Hodgins D.C. Schizophrenia and substance abuse: prevalence issues. Can. J. Psychiatry 1992, 37(10):704-710.
18. Fonder M.A., Sacco K.A., Termine A., et al. Smoking cue reactivity in schizophrenia: effects of a nicotinic receptor agonist. Biol. Psychiatry 2005, 57(7):802-808.
19. Fowler I.L., Carr V.J., Carter N.T., Lewin T.J. Patterns of current and lifetime substance abuse in schizophrenia. Schizophr. Bull. 1998, 24(3):443-445.
20. George T.P., Ziedonis D.M., Feingold A., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am. J. Psychiatry 2000, 157(11):1835-1842.
21. Giovino G.A. Epidemiology of tobacco use in the United States. Oncogene 2002, 21(48):7326-7340.
22. Goff D.C., Cather C., Evins A.E., et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry 2005, 66(2):183-194.
23. Gogek E.B. Prevalence of substance abuse in psychiatric patients. Am. J. Psychiatry 1991, 148(8):1086.
24. Goldstein M., Deutch A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 1992, 6(7):2413-2421.
25. Grant B.F., Hasin D.S., Chou S.P., Stinson F.S., Dawson D.A. Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 2004, 61(11):1107-1115.
26. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 1991, 86(9):1119-1127.
27. Heishman S.J., Singleton E.G., Pickworth W.B. Reliability and validity of a short version of the Tobacco Craving Questionnaire. Nicotine Tob. Res. 2008, 10(4):643-651.
28. Higgins S.T., Budney A.J., Hughes J.R., Bickel W.K., Lynn M., Mortensen A. Influence of cocaine use on cigarette smoking. J. Am. Med. Assoc. 1994, 272(22):1724.
29. Hoving C., Reubaset A., deVries H. Predictors of smoking stage transitions for adolescent boys and girls. Prev. Med. 2007, 44(6):485-489.
30. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: Version III - the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
31. Hser Y.I., Anglin M.D., Powers K. A 24-year follow-up of California narcotic addicts. Arch. Gen. Psychiatry 1993, 50(7):577-584.
32. Hser Y.I., McCarthy W.J., Anglin M.D. Tobacco use as a distal predictor of mortality among long-term narcotic addicts. Prev. Med. 1994, 23(1):61-69.
33. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 1986, 143(8):993-997.
34. Hurt R.D., Offord K.P., Croghan I.T., et al. Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. J. Am. Med. Assoc. 1996, 275(14):1097-1103.
35. Kalant H. Current state of knowledge about the mechanisms of alcohol tolerance. Addict. Biol. 1996, 1(2):133-141.
36. Kelly D.L., Boggs D.L., Conley R.R. Reaching for wellness in schizophrenia. Psychiatr. Clin. North Am. 2007, 30(3):453-479.
37. Kelly D.L., McMahon R.P., Wehring H.J., et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr. Bull. 2011, 37(4):832-838.
38. Kessler R.C., Crum R.M., Warner L.A., Nelson C.B., Schulenberg J., Anthony J.C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch. Gen. Psychiatry 1997, 54(4):313-321.
39. Klatte E.W., Lipscomb W.R., Rozynko V.V., Pugh L.A. Changing the legal status of mental hospital patients. Hosp. Community Psychiatry 1969, 20(7):199-202.
40. Kovasznay B. Substance abuse among veterans with a diagnosis of schizophrenia. Hosp. Community Psychiatry 1991, 42(9):948-949.
41. Leonard S., Breese C., Adams C., et al. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol. 2000, 393(1-3):237-242.
42. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. J. Am. Med. Assoc. 2000, 284(20):2606-2610.
43. Lewinsohn P.M., Rohde P., Brown R.A. Level of current and past adolescent cigarette smoking as predictors of future substance use disorders in young adulthood. Addiction 1999, 94(6):913-921.
44. Lo S., Heishman S.J., Raley H., et al. Tobacco craving in smokers with and without schizophrenia. Schizophr. Res. 2011, 127(1-3):241-245.
45. McLellan A.T., Druley K.A. Non-random relation between drugs of abuse and psychiatric diagnosis. J. Psychiatry Res. 1977, 13(3):179-184.
46. Mokdad A.H., Marks J.S., Stroup D.F., et al. Actual causes of death in the United States, 2000. J. Am. Med. Assoc. 2004, 291(10):1238-1245.
47. Office of National Drug Control Policy Baltimore, MD Profile of Drug Indicators: December 2006 2006, White House Office of National Drug Control Policy (ONDCP) Drug Policy Information Clearinghouse, Rockville, MD.
48. Owen R.R., Fischer E.P., Booth B.M., Cuffel B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr. Serv. 1996, 47(8):853-858.
49. Patton G.C., Coffey C., Carlin J.B., Sawyer S.M., Lynskey M. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 2005, 100(10):1518-1525.
50. Pristach C.A., Smith C.M. Medication compliance and substance abuse among schizophrenia patients. Hosp. Community Psychiatry 1990, 41(12):1345-1348.
51. Regier D.A., Farmer M.E., Rae D.S., et al. Comorbidity of mental disorders with alcohol and other drug abuse. J. Am. Med. Assoc. 1990, 264(19):2511-2518.
52. Reid M.S., Mickalian J.D., Delucchi K.L., Hall S.M., Berger S.P. An acute dose of nicotine enhances cue-induced cocaine craving. Drug Alcohol Depend. 1998, 49(2):95-104.
53. Reid M.S., Mickalian J.D., Delucchi K.L., Berger S.P. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology 1999, 20(3):297-307.
54. Ridgely S.M., Willenbring M.L. Application of case management to drug abuse treatment: overview of models and research issues. Progress and Issues in Case Management. NIDA Research Monograph 127, DHHS Publ. No. (ADM)92-1946 1992, Supt. of Documents, US Government Printing Office, Washington, DC. R. Ashery (Ed.).
55. Roll J.M., Higgins S.T., Budney A.J., Bickel W.K., Badger G.J. A comparison of cocaine-dependent cigarette smokers and non-smokers on demographic, drug use, and other characteristics. Drug Alcohol Depend. 1996, 40(3):195-201.
56. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: a record lineage study. Arch. Gen. Psychiatry 2007, 64:1123-1131.
57. Sanguineti V.R., Samuel S.E. Comorbid substance abuse and recovery from acute psychiatric relapse. Hosp. Community Psychiatry 1993, 44:1073-1076.
58. Schroeder S.A., Warner K.E. Don't forget tobacco. N. Engl. J. Med. 2010, 363(3):201-204.
59. Searles J.S., Alterman A.I., Purtill J.J. The detection of alcoholism in hospitalized schizophrenics: a comparison of the MAST and the MAC. Alcohol. Clin. Exp. Res. 1990, 14(4):557-560.
60. Seeman P., Bzowej N.H., Guan H.C., et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987, 1(1):5-15.
61. Simosky J.K., Stevens K.E., Freedman R. Nicotinic agonists and psychosis. Curr. Drug Targets CNS Neurol. Disord. 2002, 1(2):149-162.
62. Smith S.S., O'Hara B.F., Persico A.M., et al. Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch. Gen. Psychiatry 1992, 49(9):723-727.
63. Soyka M. Substance misuse, psychiatric disorder, and violent and disturbed behaviour. Br. J. Psychiatry 2000, 176:345-350.
64. Soyka M., Albus M., Kathman N., et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur. Arch. Psychiatry Clin. Neurosci. 1993, 242:362-372.
65. Steinberg M.L., Williams J.M., Steinberg H.R., Krejci J.A., Ziedonis D.M. Applicability of the Fagerström test for nicotine dependence in smokers with schizophrenia. Addict. Behav. 2005, 30(1):49-59.
66. Stuyt E.B., Sajbel T.A., Allen M.H. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am. J. Addict. 2006, 15(2):166-173.
67. Substance Abuse and Mental Health Services Administration Results from the 2009 national survey on drug use and health: Volume I. Summary of national findings. (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856Findings). Rockville, MD 2010.
68. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Emergency Department Trends From the Drug Abuse Warning Network, Final Estimates 1995-2002. DAWN Series: D-24, DHHS Publication No. (SMA) 03-3780, Rockville, MD 2003.
69. Swartz M.S., Swanson J.W., Hiday V.A., Borum R., Wagner H.R., Burns B.J. Violence and severe mental illness: the effects of substance abuse and non-adherence to medication. Am. J. Psychiatry 1998, 155(2):226-231.
70. Tidey J.W., Rohsenow D.J., Kaplan G.B., Swift R.M. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005, 80(2):259-265.
71. Tsuang M.T., Simpson J.C., Kronfol Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch. Gen. Psychiatry 1982, 39(2):141-147.
72. Venton B.J., Seipel A.T., Phillips P.E., et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J. Neurosci. 2006, 2(12):3206-3209.
73. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am. J. Addict. 2006, 15(5):345-355.